Publications by authors named "F Jijina"
Article Synopsis
- Low-dose emicizumab has the potential to be a cost-effective treatment for hemophilia A, particularly beneficial in developing countries.
- A study compared the safety and efficacy of low-dose emicizumab (3 mg/kg monthly) against low-dose factor VIII prophylaxis (10-20 IU/kg twice a week) in two groups of patients.
- Results showed that low-dose emicizumab resulted in significantly better outcomes in various measures, with similar treatment costs compared to low-dose FVIII, making it a promising option for improving access to hemophilia treatment.
Context: Chromosomal abnormalities play an important role in diagnosis and prognosis of hematological diseases.
Aims: The aim of the present study was to study the pattern and frequency of chromosomal aberrations in acute myeloid leukemia (AML) subgroups from western India.
Settings And Design: A retrospective study was conducted through evaluating laboratory proforma which were filled during 2005 to 2014 for diagnosis and treatment of AML subjects.
Myelodysplastic syndromes (MDS) are a group of clonal hematological disease with high risk of progression to AML. Accurate risk stratification is of importance for the proper management of MDS. Genetic lesions (Cytogenetic and Molecular mutations) are known to help in prognosticating the MDS patients.
View Article and Find Full Text PDFIntroduction: von Willebrand disease (VWD) is the common bleeding disorder with a clinically relevant bleeding prevalence of 1:10,000. von Willebrand disease patients lack both von Willebrand factor (VWF) and factor VIII (FVIII), which are critical for normal haemostasis. The conventional treatment for VWD includes desmopressin and replacement therapy with plasma derived FVIII with VWF concentrates or recombinant VWF.
View Article and Find Full Text PDFHemophagocytic lymphohistiocytosis (HLH) is a syndrome of immune dysregulation characterized by hyperactivation of the immune system, excessive cytokine secretion and severe systemic inflammation. HLH is classified as familial (FHL) when associated with mutations in , and genes. There is limited information available about the clinical and mutational spectrum of FHL patients in Indian population.
View Article and Find Full Text PDF